Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials
- 1.9k Downloads
Palonosetron, a 5-hydroxytryptamine 3 receptor antagonist (5-HT3RA) with a strong binding affinity and long half-life, has been used in numerous trials for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV). We systematically reviewed the efficacy and safety of palonosetron compared to other 5-HT3RAs in CINV prophylaxis.
A literature search of Ovid MEDLINE, EMBASE, and CENTRAL was conducted to identify randomized controlled trials (RCTs) comparing palonosetron to other 5-HT3RAs in CINV prophylaxis. Primary endpoints were the percentage of patients achieving a complete response (CR), complete control (CC), no emesis, no nausea, or taking no rescue medications. Secondary endpoints were the percentage of patients suffering from 5-HT3RA-related adverse events.
Sixteen RCTs were identified with 2,896 patients randomized to palonosetron and 3,187 patients randomized to other 5-HT3RAs. Palonosetron was consistently statistically superior in CR, CC, no emesis, or no nausea and was sometimes superior in no rescue medication. Subgroup analyses demonstrated similarity in efficacy between highly and moderately emetogenic chemotherapy cohorts. In the acute phase, statistical superiority of palonosetron was found for trials that did not allow dexamethasone; conversely, RCTs that administered dexamethasone to all patients were nonsignificant. Palonosetron was statistically significantly safer in dizziness and mean QTc interval change and similar in constipation, headache, and diarrhea. Clinical superiority of palonosetron was reached in 3 of 19 analyzed efficacy and safety endpoints.
Palonosetron is safer and more efficacious than other 5-HT3RAs. Future antiemetic guidelines should discuss the merits of including palonosetron as a first-line treatment.
KeywordsPalonosetron 5-HT3 receptor antagonist Chemotherapy-induced nausea and vomiting Efficacy Safety
We thank the generous support of the Bratty Family Fund, Michael and Karyn Goldstein Cancer Research Fund, Joseph and Silvana Melara Cancer Research Fund, and the Ofelia Cancer Research Fund.
Conflict of interest
- 5.Gralla R, Lichinitser M, Van der Vegt S et al (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14:1570–1577PubMedCrossRefGoogle Scholar
- 9.Ghosh S, Dey S (2010) Comparing different antiemetic regimens for chemotherapy induced nausea and vomiting. Int J Collab Res Int Med Pub Health 2(5):142–156Google Scholar
- 10.Botrel TEA, Clark OAC, Clark L, Paladini L, Faleiros E, Pegoretti B (2011) Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support Care Cancer 19:823–832PubMedCrossRefGoogle Scholar
- 14.Yu Z, Liu W, Wang L et al (2009) The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial. Support Care Cancer 17:99–102PubMedCrossRefGoogle Scholar
- 15.Chen YX, Qin SK, Cheng Y et al (2007) A multicenter, double-blind, randomized control clinical trial of palonosetron hydrochloride injection to prevent chemotherapy-induced nausea and vomiting. Chin Clin Oncol 12:161–165Google Scholar
- 16.Li ZQ, Xu JM, Liu DQ et al (2009) Phase II trial of hydrochloride in the prevention of moderately to severely emetogenic chemotherapy induced nausea and vomiting. Chin Clin Oncol 14:487–490Google Scholar
- 20.Kaushal J, Gupta MC, Kaushal V et al (2010) Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer. Singap Med J 51(11):871–875Google Scholar
- 23.Bernardo G, Palumbo R, Frascaroli M et al (2009) Palonosetron compared to ondansetron in the prevention of chemotherapy-induced nausea and vomiting: activity, safety, and cost-effectiveness evaluation. J Clin Oncol 27:e20573Google Scholar
- 24.Product Monograph: PrAloxi®. Mississauga: Eisai Limited; 2012.Google Scholar